BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27457831)

  • 1. Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.
    Hsu HY; Chao YK; Hsieh CH; Wen YW; Chang HK; Tseng CK; Liu YH
    Ann Thorac Surg; 2016 Nov; 102(5):1687-1693. PubMed ID: 27457831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.
    Hsu PK; Huang CS; Wang BY; Wu YC; Hsu WH
    Ann Thorac Surg; 2014 May; 97(5):1734-41. PubMed ID: 24612702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perineural invasion through the sheath in posttherapy esophagectomy specimens predicts poor survival in patients with esophageal squamous cell carcinoma.
    Tsai CY; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Eur J Surg Oncol; 2017 Oct; 43(10):1970-1976. PubMed ID: 28801062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Propensity-matched Analysis Comparing Survival After Esophagectomy Followed by Adjuvant Chemoradiation to Surgery Alone for Esophageal Squamous Cell Carcinoma.
    Hwang JY; Chen HS; Hsu PK; Chao YK; Wang BY; Huang CS; Liu CC; Wu SC
    Ann Surg; 2016 Jul; 264(1):100-6. PubMed ID: 26649580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of recurrence after oesophagectomy and postoperative chemoradiotherapy versus surgery alone for oesophageal squamous cell carcinoma.
    Hsu PK; Chen HS; Huang CS; Liu CC; Hsieh CC; Hsu HS; Wu YC; Wu SC
    Br J Surg; 2017 Jan; 104(1):90-97. PubMed ID: 27859017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.